Cargando…
Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
The use of large molecules for immunotherapy has led to exciting developments in cancer treatment, such as the development of PD-1/PD-L1 antibodies. However, small molecule targeted therapies still lack effective immune-functional classes. Ideal anticancer drugs should simultaneously generate immune...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692160/ https://www.ncbi.nlm.nih.gov/pubmed/34975325 http://dx.doi.org/10.7150/ijbs.64094 |